Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS

Boehringer IngelheimBoehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an easy-to-use, non-assert declaration for Viramune® (nevirapine). At present, twelve WHO pre-qualified manufacturers qualify for the non-assert declaration for Viramune® and Boehringer Ingelheim grants tiered pricing to 78 countries.

Under the revised IP enforcement policy, Boehringer Ingelheim will not enforce its nevirapine patent rights, provided generic versions of Viramune® are of acceptable quality and for use in eligible countries. Today's expanded IP enforcement policy will further increase access to HIV/Aids medication in emerging economies.

The decision to waive enforcement of its patent rights for nevirapine use in a total of 135 low- and middle-income countries is the result of a close cooperation between Boehringer Ingelheim and the Medicines Patent Pool (MPP). The United Nations-backed public health organisation MPP works to improve access to HIV, Hepatitis C and tuberculosis medicines in low- and middle-income countries.

"The core task of Boehringer Ingelheim is the research and development of innovative medication. We feel responsible for making innovative medicines like nevirapine accessible and affordable for patients in developing countries," explains Yew Looi Liew, Senior Vice President Emerging Markets at Boehringer Ingelheim. "Through making these medicines available we address an unmet medical need and can save lives - especially in low-income societies."

The research-driven company Boehringer Ingelheim has a significant history in the commitment of improving access to its anti-retroviral medication. The Viramune® Donation Programme was initiated in 2000 in order to facilitating access of anti-retroviral drugs for pregnant women with HIV/Aids. From its inception, the initiative reached more than two million mother-child-pairs in 164 programmes in 60 countries worldwide.

The Medicines Patent Pool (MPP) seeks to increase access to medicines by negotiating with pharmaceutical companies for voluntary licenses on their medicines patents. The work of the MPP has been endorsed by the World Health Organization, UNAIDS, The Global Fund to Fight Aids, Tuberculosis and Malaria, and the Group of Eight (G8) Industrialised Nations (France, Germany, Italy, United Kingdom, Japan, United States, Canada and Russia). The MPP was founded and continues to be funded by the innovative financing mechanism UNITAID.

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative "Making More Health" while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent ofnet sales.

Most Popular Now

Novartis confirms 5 year data for first and only f…

Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension stud...

Researchers develop microneedle patch for flu vacc…

A National Institutes of Health-funded study led by a team at the Georgia Institute of Technology and Emory University has shown that an influenza vaccine can produce rob...

Jardiance® (empagliflozin) analysis reinforces est…

An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (...

Alzheimer's and Parkinson's spurred by same enzyme

Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors. But at ...

Researchers publish new findings on influence of h…

Poor diet is associated with 80% of colorectal cancer cases, but the exact pathways by which diet leads to cancer are not known. In a newly published study, Cleveland Cli...

Merck awards €1.25 million to research projects th…

Merck, a leading science and technology company, today announced its commitment to award €1.25 million to research projects in the field of fertility, supporting the adva...

FDA tackles drug competition to improve patient ac…

Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower...

Trials show unique stem cells a potential asthma t…

A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma. The Mo...

Roche acquires mySugr to form a leading open platf…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. Counting more than one million users globally...

Older Americans don't get - or seek - enough help …

The majority of Americans over age 50 take two or more prescription medicines to prevent or treat health problems, and many of them say the cost weighs on their budget, a...

Novartis CAR-T cell therapy CTL019 unanimously (10…

Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisag...

New brain cancer drug targets revealed

Researchers from Case Western Reserve University School of Medicine and The Cleveland Clinic designed a way to screen brain tumor cells and identify potential drug target...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]